» Articles » PMID: 38426087

Immune Escape and Metastasis Mechanisms in Melanoma: Breaking Down the Dichotomy

Overview
Journal Front Immunol
Date 2024 Mar 1
PMID 38426087
Authors
Affiliations
Soon will be listed here.
Abstract

Melanoma is one of the most lethal neoplasms of the skin. Despite the revolutionary introduction of immune checkpoint inhibitors, metastatic spread, and recurrence remain critical problems in resistant cases. Melanoma employs a multitude of mechanisms to subvert the immune system and successfully metastasize to distant organs. Concerningly, recent research also shows that tumor cells can disseminate early during melanoma progression and enter dormant states, eventually leading to metastases at a future time. Immune escape and metastasis have previously been viewed as separate phenomena; however, accumulating evidence is breaking down this dichotomy. Recent research into the progressive mechanisms of melanoma provides evidence that dedifferentiation similar to classical epithelial to mesenchymal transition (EMT), genes involved in neural crest stem cell maintenance, and hypoxia/acidosis, are important factors simultaneously involved in immune escape and metastasis. The likeness between EMT and early dissemination, and differences, also become apparent in these contexts. Detailed knowledge of the mechanisms behind "dual drivers" simultaneously promoting metastatically inclined and immunosuppressive environments can yield novel strategies effective in disabling multiple facets of melanoma progression. Furthermore, understanding progression through these drivers may provide insight towards novel treatments capable of preventing recurrence arising from dormant dissemination or improving immunotherapy outcomes.

Citing Articles

Inflammasome activation in melanoma progression: the latest update concerning pathological role and therapeutic value.

Pluetrattanabha N, Direksunthorn T, Ahmad I, Jyothi S, Shit D, Singh A Arch Dermatol Res. 2025; 317(1):258.

PMID: 39820618 DOI: 10.1007/s00403-025-03802-1.


Amelanotic Melanoma-Biochemical and Molecular Induction Pathways.

Misiag P, Molik K, Kisielewska M, Typek P, Skowron I, Karwowska A Int J Mol Sci. 2024; 25(21).

PMID: 39519055 PMC: 11546312. DOI: 10.3390/ijms252111502.


Enhanced Anti-Melanoma Activity of Nutlin-3a Delivered via Ethosomes: Targeting p53-Mediated Apoptosis in HT144 Cells.

Romani A, Lodi G, Casciano F, Gonelli A, Secchiero P, Zauli G Cells. 2024; 13(20.

PMID: 39451196 PMC: 11506859. DOI: 10.3390/cells13201678.


Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.

Shan Z, Liu F Front Immunol. 2024; 15:1441410.

PMID: 39234260 PMC: 11373357. DOI: 10.3389/fimmu.2024.1441410.


Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies.

Limonta P, Chiaramonte R, Casati L Cancers (Basel). 2024; 16(16).

PMID: 39199632 PMC: 11352669. DOI: 10.3390/cancers16162861.


References
1.
Justus C, Yang L . GPR4 decreases B16F10 melanoma cell spreading and regulates focal adhesion dynamics through the G13/Rho signaling pathway. Exp Cell Res. 2015; 334(1):100-13. DOI: 10.1016/j.yexcr.2015.03.022. View

2.
Kulesa P, Morrison J, Bailey C . The neural crest and cancer: a developmental spin on melanoma. Cells Tissues Organs. 2013; 198(1):12-21. PMC: 3809092. DOI: 10.1159/000348418. View

3.
Rosenbaum S, Tiago M, Caksa S, Capparelli C, Purwin T, Kumar G . SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 2021; 37(10):110085. PMC: 8720266. DOI: 10.1016/j.celrep.2021.110085. View

4.
Wu R, Wang C, Li Z, Xiao J, Li C, Wang X . SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. J Immunother Cancer. 2020; 8(2). PMC: 7651737. DOI: 10.1136/jitc-2020-001037. View

5.
Tudrej K, Czepielewska E, Kozlowska-Wojciechowska M . SOX10-MITF pathway activity in melanoma cells. Arch Med Sci. 2017; 13(6):1493-1503. PMC: 5701683. DOI: 10.5114/aoms.2016.60655. View